Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field, showing how they are being used as key levers for ADC drug developers to pull to create ADCs with a widened therapeutic index. The inaugural ADC Linker & Conjugation Summit has been specifically designed to drive innovations in […]

Bringing together technical experts from biopharma and academia, the brand-new RNA Assay Development & Screening Summit has been curated to support in-house assay development and screening strategies to find new RNA targets, and ultimately determine biological effect in a manner that supports progression from early discovery to drug candidate. Developed in collaboration with experts in the field, join 60+ […]

Last year was momentous for the cell therapy field: it was the year that CAR-T therapies became CURATIVE. This decade of success has resulted in explosive investment into the development of CAR and TCR based approaches to ensure more patients around the world can benefit from these lifesaving therapies.   The 8th CAR-TCR Summit is returning to Boston as […]

Rapid development and rising demand of oligonucleotide drugs is fuelling revolutionary steps in biopharma investment and technology advancement for pipeline progression. The prospect of defining impurities and suitable CQAs for long-term scalable manufacturing looks to propel oligonucleotide development to patients at a much faster rate. The 2nd Oligonucleotides CMC & Analytical Development Summit returns this […]

The development of next-generation drug-based approaches to treat inner ear disorders is gaining momentum, with multiple INDs approved in the last six months and big pharma making plays to acquire innovative biotechs working on hearing loss. However, in a space that has also had to battle with multiple clinical failures, there’s a genuine need for […]